Skip to main content

Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

The Original Article was published on 30 May 2019

Correction to: BMC Cancer

https://doi.org/10.1186/s12885-019-5687-0

Following publication of the original article [1], the authors reported the following errors in the article.

  1. 1)

    In Table 2, the layout has been updated. The corrected Table 2 is supplied below:

  2. 2)

    The legend for Fig. 3 has been adapted for clearer readability. The updated legend is as follows:

  3. 3)

    The competing interests statement has been updated below.

Table 2 Progression-free survival by HER2 expression subgroups
Fig. 3
figure 1

Kaplan–Meier curve of PFS in subgroups defined by the presence/absence of negatively impacting biomarkers.*

*Biomarkers were considered negatively prognostic of response to HER2-targeted treatment based on their association with a numerical decrease in PFS. Specifically, these included expression of mutated PIK3CA, low HER2 mRNA level (≤median), and focal HER2 distribution. Patients without negative markers were those with nonmutated PIK3CA, high HER2 mRNA levels (>median), and non-focal (i.e., heterogeneous or homogenous) distribution of HER2. Patients with negative markers were those with mutated PIK3CA, low HER2 mRNA levels (≤median), and focal HER2 distribution. HER2 human epidermal growth factor receptor 2, PIK3CA phosphoinositide 3-kinase catalytic subunit alpha, PFS progression-free survival, T-DM1 trastuzumab emtansine

Reference

  1. Perez, et al. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2- positive advanced breast cancer. BMC Cancer. 2019;19:517 https://doi.org/10.1186/s12885-019-5687-0.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Edith A. Perez.

Ethics declarations

Competing interests

EAP was a salaried employee of Genentech, Inc. at the time this work was prepared and owns stock in F. Hoffmann-La Roche Ltd. SLdH, SS, and MP are salaried employees of F. Hoffmann-La Roche Ltd. SS and MP own stock in F. Hoffmann-La Roche Ltd. WE has served as a consultant and on Speakers’ Bureaus for F. Hoffmann-La Roche Ltd. CHB has served as a consultant for F. Hoffmann-La Roche Ltd., Pfizer, GlaxoSmithKline, Novartis, Boehringer Ingelheim, and Eisai and has received research funding from Amgen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pfizer, F. Hoffmann-La Roche/Genentech, Eisai, Lilly, Sanofi-Aventis, and Celgene. MT has received research funding from Chugai Pharmaceutical. PFC has served on Speakers’ Bureaus for Novartis, F. Hoffmann-La Roche Ltd., and AstraZeneca and has received research funding from F. Hoffmann-La Roche Ltd. and Novartis. MM has received honoraria from and has served as a consultant for F. Hoffmann-La Roche Ltd. TP has received honoraria and research funding from F. Hoffmann-La Roche Ltd., Pfizer, and Novartis. He has also served as a consultant for F. Hoffmann-La Roche Ltd. XBP has received honoraria from F. Hoffmann-La Roche Ltd., GlaxoSmithKline, Amgen, Novartis, Pierre Fabre, and Eisai. He has also served as a consultant for F. Hoffmann-La Roche Ltd., Amgen, Novartis, Pierre Fabre, and Eisai. Y-HI, HAB, and PAE have nothing to disclose.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Perez, E.A., de Haas, S.L., Eiermann, W. et al. Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer. BMC Cancer 19, 620 (2019). https://doi.org/10.1186/s12885-019-5831-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12885-019-5831-x